## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 3.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($541.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Intuitive Surgical stock today: ISRG slips into 2026 as New Year’s Day shuts Wall Street**
- Source: ts2.tech | 20260101T221314 | Somewhat-Bearish | Relevance: 100%
- Intuitive Surgical (ISRG) stock closed lower in the final 2025 session, falling 1.1% to $566.36, as Wall Street shut down for New Year’s Day. Investors are now focused on January catalysts, including the company's Q4 earnings call scheduled for January 22, and whether procedure-driven demand for robotic surgery will maintain investor confidence. The stock's performance in early January will be closely watched for signs of continued profit-taking or sustained support.

**2. ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery?**
- Source: The Globe and Mail | 20251231T140833 | Bullish | Relevance: 100%
- Intuitive Surgical's single-port (SP) platform saw a 91% year-over-year growth in procedures during Q3 2025, driven by strong adoption in Korea and expanding indications in the U.S. This surge, coupled with regulatory advancements and positive clinical evidence, suggests SP surgery is transitioning from a niche to a more mainstream application, potentially serving as an incremental growth driver for the company. While the U.S. market is still in early stages, regulatory submissions and initial domestic use in new procedures like colorectal and thoracic surgeries are broadening its addressable market.

**3. Intuitive Surgical stock falls today: what’s driving ISRG and what investors watch next**
- Source: ts2.tech | 20260102T210847 | Somewhat-Bearish | Relevance: 100%
- Intuitive Surgical (ISRG) stock fell 1% today, trading at $560.61, as investors show fresh sensitivity to valuation after a strong 2025. The decline appears more stock-specific, despite a mixed market, and investors are looking ahead to next week's U.S. jobs and inflation data, as well as mid-January healthcare conference updates. A change in the Chief Digital Officer's reporting structure was also noted.

**4. Intuitive Surgical, Inc. $ISRG Shares Acquired by SteelPeak Wealth LLC**
- Source: MarketBeat | 20260102T124257 | Bullish | Relevance: 100%
- SteelPeak Wealth LLC significantly increased its stake in Intuitive Surgical, Inc. by 28.7% in Q3, acquiring an additional 9,364 shares for a total of 41,993 shares valued at approximately $18.78 million. This acquisition follows Intuitive Surgical's strong Q3 performance, where it surpassed earnings expectations with an EPS of $2.40 and revenue of $2.51 billion, marking a 22.9% year-over-year increase. Despite recent insider share sales totaling $63.53 million, institutional investors maintain a substantial 83.64% ownership of the company.

**5. Roberts Wealth Advisors LLC Takes Position in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20260101T133059 | Somewhat-Bullish | Relevance: 100%
- Roberts Wealth Advisors LLC has initiated a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by acquiring 8,152 shares valued at approximately $3.65 million in Q3. This move contributes to institutional investors now owning about 83.64% of the company's stock, even as some insiders have been selling shares. Analysts generally rate ISRG as a "Moderate Buy" with an average price target of $611.08, following the company's strong Q3 earnings beat.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.5M in recent transactions.
3. Valuation stretched: PEG 3.5x requires aggressive growth execution.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.55 signals overvaluation risk, limited margin of safety. Forward P/E 57.6x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $201.5B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.55 |
| Forward P/E | 57.6 |
| Current P/E | 65.0 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.6% to -1.1% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-1.33), momentum weakening. RSI neutral at 49. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.15% (CS: 19) | Neutral |
| RSI_14 | 49.2 | Neutral |
| MACD Histogram | -1.33 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $561.98
- **Stop Loss:** $541.80 (3.6% risk)
- **Target:** $582.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $39,900.58
- **Portfolio %:** 39.90%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*